Equity Profile

TWST

Twist Bioscience Corporation

Health CareBiotechnology$7.9B

Aug3Mon

Pre-Earnings Brief

UpcomingQ3-2026Pre-Market9:00 AM EDT

Company Snapshot

Twist Bioscience Corporation is a biotechnology company specializing in DNA synthesis and gene editing technologies. With a market cap of $8 billion, it plays a crucial role in advancing genetic research and applications across various sectors, including healthcare and agriculture.

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.18

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$115M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2 2026, Twist Bioscience reported an EPS of $-0.71, missing estimates by a significant margin. The stock reacted negatively, dropping nearly 7% the following day.

Management Promises & Guidance

Focus on improving product development timelines.
Commitment to expanding customer base in the healthcare sector.
Plans to enhance operational efficiency to reduce costs.

Expectations

Wall Street Expectations

Analysts expect a challenging quarter for Twist Bioscience, with a consensus EPS of $-0.18 and revenue at $115 million. The company has struggled with profitability, leading to cautious sentiment among investors.

Bull Case

If Twist can exceed revenue expectations and show signs of narrowing losses, it could restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports worse-than-expected earnings and revenue, it may further erode trust in management's ability to execute its strategy.

Key Metrics to Watch

EPS

$-0.18

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$115M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.18?

A better-than-expected EPS could signal improved operational efficiency and restore some investor confidence.

What specific revenue figures can management provide to support the $115 million consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Twist to surprise on the upside given recent advancements in their technology and product offerings.

Supporting Evidence

The company has made significant strides in its product pipeline that could lead to unexpected revenue growth.

Options pricing suggests a larger move than historical averages, indicating that traders are anticipating a significant event.

Past performance shows that the company has occasionally exceeded expectations despite a challenging environment.

Key Risk

If the company reports an EPS better than $-0.16, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching profitability and revenue growth as indicators of the company's ability to navigate its challenges.

Bull Confirmed If

An EPS of $-0.16 or better, along with revenue exceeding $115 million, would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than $-0.20, coupled with revenue below $114 million, would support a bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±39.26%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in significant volatility around the earnings report, suggesting that traders expect a large price movement in either direction.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations and raises guidance, history suggests a potential stock increase of around 0.91% on the following day.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement.

Miss

If the company misses expectations, history indicates a likely decline of about 6.11% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technology advancements.
2Details on customer acquisition and retention strategies.
3Management's outlook on market demand for DNA synthesis.
4Insights into cost management efforts and operational efficiency.
5Any commentary on partnerships or collaborations that could drive growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.18

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$115M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2 2026, Twist Bioscience reported an EPS of $-0.71, missing estimates by a significant margin. The stock reacted negatively, dropping nearly 7% the following day.

Management Promises & Guidance

Focus on improving product development timelines.
Commitment to expanding customer base in the healthcare sector.
Plans to enhance operational efficiency to reduce costs.

Expectations

Wall Street Expectations

Bull Case

If Twist can exceed revenue expectations and show signs of narrowing losses, it could restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports worse-than-expected earnings and revenue, it may further erode trust in management's ability to execute its strategy.

Key Metrics to Watch

EPS

$-0.18

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$115M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.18?

A better-than-expected EPS could signal improved operational efficiency and restore some investor confidence.

What specific revenue figures can management provide to support the $115 million consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Twist to surprise on the upside given recent advancements in their technology and product offerings.

Supporting Evidence

The company has made significant strides in its product pipeline that could lead to unexpected revenue growth.

Options pricing suggests a larger move than historical averages, indicating that traders are anticipating a significant event.

Past performance shows that the company has occasionally exceeded expectations despite a challenging environment.

Key Risk

If the company reports an EPS better than $-0.16, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching profitability and revenue growth as indicators of the company's ability to navigate its challenges.

Bull Confirmed If

An EPS of $-0.16 or better, along with revenue exceeding $115 million, would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than $-0.20, coupled with revenue below $114 million, would support a bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±39.26%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in significant volatility around the earnings report, suggesting that traders expect a large price movement in either direction.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations and raises guidance, history suggests a potential stock increase of around 0.91% on the following day.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement.

Miss

If the company misses expectations, history indicates a likely decline of about 6.11% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technology advancements.
2Details on customer acquisition and retention strategies.
3Management's outlook on market demand for DNA synthesis.
4Insights into cost management efforts and operational efficiency.
5Any commentary on partnerships or collaborations that could drive growth.